Galapagos NV – NASDAQ:GLPG

Add to watchlist

$32.1

+4.80

+17.58%

Market closed

Open in 3 days

+1.11%

month

+1.11%

quarter

-32.77%

year

Market Cap	1.75B
Enterprise value	1.86B

P/E	-10.47
EV/Sales	3.22
EV/EBITDA	27.85
Price/Sales	3.70
Price/Book	0.79
PEG ratio	-0.15
EPS	0.95

Revenue	123.28M
EBITDA	-51.61M
Income	278.71M
Revenue Q/Q	-65.09%
Revenue Y/Y	-77.49%

Profit margin	0.96%
Oper. margin	-82.54%
Gross margin	98.46%
EBIT margin	-82.54%
EBITDA margin	-41.86%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Galapagos NV (NASDAQ:GLPG): Profit margin
Jun 2023	149.95M	5.10M	3.4%
Sep 2023	120.02M	25.83M	21.52%
Dec 2023	-209.12M	157.55M	-75.34%
Mar 2024	62.43M	90.22M	144.51%

Galapagos NV Financials Estimate

Q Y

Galapagos NV (NASDAQ:GLPG): Analyst Estimates
Mar 2024	62.43M	90.22M	144.51%
Sep 2025	60.13M	5.18M	8.63%
Dec 2025	69.93M	-13.04M	-18.65%
Dec 2025	60.13M	5.18M	8.63%

Analysts Price target
Financials & Ratios estimates

Galapagos NV (NASDAQ:GLPG): Earnings per share (EPS)
2023-05-04	-0.87	0.43
2023-08-03	1.08	-0.31

Galapagos NV (NASDAQ:GLPG): Debt to assets
Jun 2023	4522340000	1.93B	42.86%
Sep 2023	4451336000	1.82B	41.11%
Dec 2023	4357396000	1.56B	35.84%
Mar 2024	4361379000	1.46B	33.62%

Galapagos NV (NASDAQ:GLPG): Cash Flow
Jun 2023	-125.41M	100.90M	-1.55M
Sep 2023	-118.81M	182.53M	-2.06M
Dec 2023	-66.86M	76.40M	-1.19M
Mar 2024	-117.78M	25.01M	-1.16M

Galapagos NV alternative data

Galapagos NV
Employees

Galapagos NV (NASDAQ:GLPG): Employee count
Aug 2023	1,338
Sep 2023	1,233
Oct 2023	1,233
Nov 2023	1,233
Dec 2023	1,338
Jan 2024	1,338
Feb 2024	1,338
Mar 2024	1,338
Apr 2024	1,338
May 2024	1,123
Jun 2024	1,123
Jul 2024	1,123

Galapagos NV
Hedge Funds Holdings Q1 2022

24.39% +3.66%

of GLPG is owned by hedge funds

86 +3

hedge funds hold GLPG stock

12.71M +1.90M

shares is hold by hedge funds

GLPG hedge funds holdings changes

Status	Patent	Filling date	Issue date
Application	Application Prodrug Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use Filling date: 27 May 2022 Issue date: 8 Sep 2022	27 May 2022	8 Sep 2022
Application	Application NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES Filling date: 25 May 2020 Issue date: 28 Jul 2022	25 May 2020	28 Jul 2022
Application	Application NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS. Filling date: 12 Nov 2021 Issue date: 21 Jul 2022	12 Nov 2021	21 Jul 2022
Application	Application NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS Filling date: 24 Mar 2020 Issue date: 14 Jul 2022	24 Mar 2020	14 Jul 2022
Application	Application NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF KIDNEY DISEASES Filling date: 21 Apr 2020 Issue date: 30 Jun 2022	21 Apr 2020	30 Jun 2022
Application	Application NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS Filling date: 24 Mar 2020 Issue date: 23 Jun 2022	24 Mar 2020	23 Jun 2022
Application	Application PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES Filling date: 3 Sep 2021 Issue date: 2 Jun 2022	3 Sep 2021	2 Jun 2022
Grant	Grant Utility: Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use Filling date: 2 Jun 2020 Issue date: 31 May 2022	2 Jun 2020	31 May 2022
Grant	Grant Utility: Compounds and pharmaceutical compositions thereof for the treatment of diseases Filling date: 26 Nov 2018 Issue date: 24 May 2022	26 Nov 2018	24 May 2022
Application	Application PYRAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF PASK Filling date: 17 Feb 2020 Issue date: 12 May 2022	17 Feb 2020	12 May 2022

Galapagos NV
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 3 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 23 Feb 2024	Q4 2023 Earnings Call Transcript
Q3 2023 5 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 4 Aug 2023	Q2 2023 Earnings Call Transcript

GLPG earnings call transcripts

Galapagos NV
Executives

Insider	Age	Compensation
Mr. Onno Van De Stolpe (1959) Co-Founder, Chairman of the Management Board, MD & Chief Executive Officer	66	$1,000,000
Mr. Bart Filius M.B.A., MBA (1970) Pres, Chief Operating Officer & Member of Management Board	55	$642,120
Dr. Walid Abi-Saab (1965) Chief Medical Officer & Member of Management Board	60	$613,110
Dr. Andre Hoekema (1957) Chief Bus. Officer & Member of Management Board	68	$578,000

Galapagos NV
Latest News

Saturday, 7 December 2024
12:30	Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma	globenewswire.com
Tuesday, 5 November 2024
16:01	Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024	globenewswire.com
Thursday, 31 October 2024
15:50	Galapagos NV (GLPG) Q3 2024 Earnings Call Transcript	seekingalpha.com
Wednesday, 30 October 2024
16:01	Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update	globenewswire.com
Monday, 7 October 2024
01:00	Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth	globenewswire.com
Tuesday, 1 October 2024
06:00	Excellos Selected as Decentralized Manufacturing Unit to Support Galapagos' CAR-T Cell Therapy Clinical Study Close to Cancer Treatment Centers in the San Diego Area	businesswire.com
Monday, 30 September 2024
16:01	Galapagos receives transparency notification from EcoR1 Capital	globenewswire.com
Monday, 16 September 2024
16:01	Galapagos receives transparency notification from EcoR1 Capital	globenewswire.com
Tuesday, 3 September 2024
16:01	Galapagos receives transparency notification from FMR LLC	globenewswire.com
Monday, 26 August 2024
10:21	Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats	investors.com
Friday, 23 August 2024
15:49	Galapagos: CAR-T Biotech To Change Landscape With GLPG5101 And Beyond	seekingalpha.com
08:45	Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study	zacks.com
01:00	Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma	globenewswire.com
Tuesday, 20 August 2024
16:01	Galapagos receives transparency notification from FMR LLC	globenewswire.com
Friday, 2 August 2024
13:25	Galapagos NV (GLPG) Q2 2024 Earnings Call Transcript	seekingalpha.com
Thursday, 1 August 2024
16:01	BridGene Biosciences Expands Strategic Collaboration with Galapagos to Develop Selective Oral SMARCA2 PROTAC in Precision Oncology	prnewswire.com
16:01	Galapagos reports half-year 2024 financial results and provides second quarter business update	globenewswire.com
Friday, 14 June 2024
16:01	Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024	globenewswire.com
Thursday, 30 May 2024
16:01	Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications	newsfilecorp.com
16:01	Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications	globenewswire.com
Thursday, 16 May 2024
16:01	Galapagos creates new subscription right plans	globenewswire.com
Wednesday, 15 May 2024
16:01	Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos' decentralized CAR-T manufacturing network in the U.S.	globenewswire.com
Saturday, 4 May 2024
11:51	Galapagos NV (GLPG) Q1 2024 Earnings Call Transcript	Seeking Alpha
Wednesday, 3 April 2024
10:36	After Plunging -7.94% in 4 Weeks, Here's Why the Trend Might Reverse for Galapagos (GLPG)	Zacks Investment Research
Monday, 18 March 2024
10:36	Down -14.35% in 4 Weeks, Here's Why Galapagos NV (GLPG) Looks Ripe for a Turnaround	Zacks Investment Research
Friday, 15 December 2023
09:46	Buy These 4 Low-Beta Stocks to Counter Market Volatility	Zacks Investment Research
Wednesday, 13 December 2023
07:32	New Strong Buy Stocks for December 13th	Zacks Investment Research
Sunday, 5 November 2023
09:14	Galapagos NV (GLPG) Q3 2023 Earnings Call Transcript	Seeking Alpha
Friday, 4 August 2023
16:30	Galapagos NV (GLPG) Q2 2023 Earnings Call Transcript	Seeking Alpha
Saturday, 6 May 2023
01:59	Galapagos Stands Strong On Jyseleca Positive Clinical Data	Seeking Alpha

Ideas & Opinions

Seeking Alpha 6 May 2023

Galapagos Stands Strong On Jyseleca Positive Clinical Data
Seeking Alpha 11 Feb 2023

Galapagos: Crohn's Disease Trial Failure, Still Maintaining A Buy Rating
Seeking Alpha 8 Feb 2023

Galapagos: Deeply Into Negative EV Territory, Exciting BD Optionality, Buy
Seeking Alpha 1 Feb 2023

MorphoSys: Negative Enterprise Value Biotech, But Lack Of Near-Term Catalyst
Seeking Alpha 31 Dec 2022

Galapagos: Slow Transformation, But Led By An Expert
Seeking Alpha 10 Oct 2022

Galapagos: Trading At Discount To Cash With A Fast-Growing Marketed Product
Seeking Alpha 15 Jun 2022

Takeda Pharmaceutical Vs. Gilead Sciences: Who Is The Dividend King?
Seeking Alpha 19 May 2022

Galapagos: Can The Company Turn Around?
Seeking Alpha 22 Feb 2022

Galapagos: A History Of Disruptive Failures
Seeking Alpha 2 Dec 2021

Galapagos: The Investment Thesis Is More Appealing Than Ever

Frequently Asked Questions (FAQ)

What's the price of Galapagos NV stock today?

One share of Galapagos NV stock can currently be purchased for approximately $32.1.
When is Galapagos NV's next earnings date?

Unfortunately, Galapagos NV's (GLPG) next earnings date is currently unknown.
Does Galapagos NV pay dividends?

No, Galapagos NV does not pay dividends.
How much money does Galapagos NV make?

Galapagos NV has a market capitalization of 1.75B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 52.56% to 239.72M US dollars. Galapagos NV earned 211.7M US dollars in net income (profit) last year or -$0.31 on an earnings per share basis.
What is Galapagos NV's stock symbol?

Galapagos NV is traded on the NASDAQ under the ticker symbol "GLPG".
What is Galapagos NV's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Galapagos NV?

Shares of Galapagos NV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Galapagos NV's key executives?
Galapagos NV's management team includes the following people:
- Mr. Onno Van De Stolpe Co-Founder, Chairman of the Management Board, MD & Chief Executive Officer(age: 66, pay: $1,000,000)
- Mr. Bart Filius M.B.A., MBA Pres, Chief Operating Officer & Member of Management Board(age: 55, pay: $642,120)
- Dr. Walid Abi-Saab Chief Medical Officer & Member of Management Board(age: 60, pay: $613,110)
- Dr. Andre Hoekema Chief Bus. Officer & Member of Management Board(age: 68, pay: $578,000)
Is Galapagos NV founder-led company?

Yes, Galapagos NV is a company led by its founder Mr. Onno Van De Stolpe.
How many employees does Galapagos NV have?

As Jul 2024, Galapagos NV employs 1,123 workers, which is 16% less then previous quarter.
When Galapagos NV went public?

Galapagos NV is publicly traded company for more then 13 years since IPO on 27 Feb 2012.
What is Galapagos NV's official website?

The official website for Galapagos NV is glpg.com.
How can i contact Galapagos NV?

Galapagos NV can be reached via phone at +32 15 34 29 00.

Galapagos NV

glpg.com

Exchange:

NASDAQ

Full time employees:

1,123

Industry:

Biotechnology

Sector:

Healthcare

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

+32 15 34 29 00

Generaal De Wittelaan L11 A3
Mechelen, 2800

CIK: 0001421876
ISIN: US36315X1019
CUSIP: 36315X101